Matthieu Billuart
Overview
Explore the profile of Matthieu Billuart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hubin P, Van den Borre L, Braeye T, Cavillot L, Billuart M, Stouten V, et al.
Vaccine X
. 2024 May;
18:100496.
PMID: 38779406
Vaccination has played a major role in overcoming the COVID-19 pandemic. However, vaccination status can be influenced by demographic and socio-economic factors at individual and area level. In the context...
2.
Cavillot L, van Loenhout J, Devleesschauwer B, Wyndham-Thomas C, Van Oyen H, Ghattas J, et al.
J Epidemiol Community Health
. 2023 Dec;
PMID: 38148149
Background: Recent studies have identified important social inequalities in SARS-CoV-2 infections and related COVID-19 outcomes in the Belgian population. The aim of our study was to investigate the sociodemographic and...
3.
Vermeiren E, van Loenhout J, Nasiadka L, Stouten V, Billuart M, Van Evercooren I, et al.
BMC Res Notes
. 2023 Nov;
16(1):328.
PMID: 37951923
Objective: This study aimed to investigate factors influencing the uptake of first and second COVID-19 booster vaccines among adults in Belgium, particularly age, sex, region of residence and laboratory confirmed...
4.
Braeye T, van Loenhout J, Brondeel R, Stouten V, Hubin P, Billuart M, et al.
Euro Surveill
. 2023 Jun;
28(26).
PMID: 37382885
BackgroundThe Belgian COVID-19 vaccination campaign aimed to reduce disease spread and severity.AimWe estimated SARS-CoV-2 variant-specific vaccine effectiveness against symptomatic infection (VEi) and hospitalisation (VEh), given time since vaccination and prior...
5.
Braeye T, Catteau L, Brondeel R, van Loenhout J, Proesmans K, Cornelissen L, et al.
Vaccine
. 2023 Apr;
41(20):3292-3300.
PMID: 37085456
Objectives: Vaccine effectiveness against transmission (VET) of SARS-CoV-2-infection can be estimated from secondary attack rates observed during contact tracing. We estimated VET, the vaccine-effect on infectiousness of the index case...
6.
Braeye T, Catteau L, Brondeel R, van Loenhout J, Proesmans K, Cornelissen L, et al.
Vaccine
. 2022 Apr;
40(22):3027-3037.
PMID: 35459558
Background: During the first half of 2021, we observed high vaccine effectiveness (VE) against SARS-CoV2-infection. The replacement of the alpha-'variant of concern' (VOC) by the delta-VOC and uncertainty about the...
7.
Stouten V, Hubin P, Haarhuis F, van Loenhout J, Billuart M, Brondeel R, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458532
The objective of this study was to investigate the incidence and risk factors associated with COVID-19 vaccine breakthrough infections. We included all persons ≥18 years that had been fully vaccinated...